IS2670B - Bóluefni og notkun þar á til meðhöndlunar á blandaðri hreyfitaugahrörnun - Google Patents

Bóluefni og notkun þar á til meðhöndlunar á blandaðri hreyfitaugahrörnun

Info

Publication number
IS2670B
IS2670B IS7296A IS7296A IS2670B IS 2670 B IS2670 B IS 2670B IS 7296 A IS7296 A IS 7296A IS 7296 A IS7296 A IS 7296A IS 2670 B IS2670 B IS 2670B
Authority
IS
Iceland
Prior art keywords
cop
vaccines
treatment
tyr
glu
Prior art date
Application number
IS7296A
Other languages
English (en)
Other versions
IS7296A (is
Inventor
Michal Eisenbach-Schwartz
Esther Yoles
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of IS7296A publication Critical patent/IS7296A/is
Publication of IS2670B publication Critical patent/IS2670B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
IS7296A 2001-12-06 2004-06-03 Bóluefni og notkun þar á til meðhöndlunar á blandaðri hreyfitaugahrörnun IS2670B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33613901P 2001-12-06 2001-12-06
PCT/IL2002/000979 WO2003047500A2 (en) 2001-12-06 2002-12-05 Vaccine and method for treatment of motor neurone diseases

Publications (2)

Publication Number Publication Date
IS7296A IS7296A (is) 2004-06-03
IS2670B true IS2670B (is) 2010-09-15

Family

ID=23314742

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7296A IS2670B (is) 2001-12-06 2004-06-03 Bóluefni og notkun þar á til meðhöndlunar á blandaðri hreyfitaugahrörnun

Country Status (24)

Country Link
US (1) US7351686B2 (is)
EP (1) EP1429800B1 (is)
JP (1) JP4542339B2 (is)
KR (1) KR20040081431A (is)
CN (2) CN102151330B (is)
AT (1) ATE422362T1 (is)
AU (1) AU2002353486B2 (is)
CA (1) CA2469092C (is)
CY (1) CY1109044T1 (is)
DE (1) DE60231131D1 (is)
DK (1) DK1429800T3 (is)
ES (1) ES2322566T3 (is)
HK (1) HK1067043A1 (is)
HU (1) HU228207B1 (is)
IL (1) IL160105A0 (is)
IS (1) IS2670B (is)
MX (1) MXPA04005537A (is)
NO (1) NO336231B1 (is)
NZ (1) NZ533356A (is)
PL (1) PL205469B1 (is)
PT (1) PT1429800E (is)
RU (1) RU2303996C2 (is)
SI (1) SI1429800T1 (is)
WO (1) WO2003047500A2 (is)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7399740B2 (en) 2001-06-28 2008-07-15 Yeda Research And Development Co. Ltd. Poly-Glu,Tyr for neuroprotective therapy
ATE548045T1 (de) * 2003-01-07 2012-03-15 Yeda Res & Dev Vakzine in augentropfenform enthaltend copolymer 1 für die therapeutische immunisierung
CA2546077C (en) 2003-11-12 2016-07-05 Yeda Research And Development Co. Ltd. Vaccine and method for treatment of neurodegenerative diseases
PL1701730T3 (pl) 2003-12-09 2014-04-30 Yeda Res & Dev Sposób i szczepionka zawierająca kopolimer 1 do leczenia zaburzeń psychicznych
EP1778286A4 (en) * 2004-03-03 2009-04-08 Teva Pharma COMBINATION THERAPY WITH ACETATE OF GLATIRAMER AND RILUZOLE
CA2565819A1 (en) * 2004-05-07 2005-12-01 Peptimmune, Inc. Methods of treating disease with random copolymers
US7655221B2 (en) 2004-05-07 2010-02-02 Peptimmune, Inc. Methods of treating disease with random copolymers
US8165823B2 (en) 2005-07-15 2012-04-24 Novartis Ag Pamps, pathogen associated molecular patterns
CN100448481C (zh) * 2006-06-22 2009-01-07 中国科学院遗传与发育生物学研究所 xCT蛋白及其编码基因的新用途
US8193147B2 (en) 2007-09-24 2012-06-05 Hadasit Medical Research Services & Development Ltd. Use of copolymer 1 for treatment of muscular dystrophy
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) * 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
KR20140019296A (ko) 2010-10-11 2014-02-14 테바 파마슈티컬 인더스트리즈 리미티드 글라티라머 아세테이트에 대한 임상 반응의 예측성 바이오마커로서의 사이토카인 바이오마커
ES2601892T3 (es) 2011-04-21 2017-02-16 Mapi Pharma Limited Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes
EP2765857A4 (en) 2011-10-10 2015-12-09 Teva Pharma SIMPLE NUCLEOTIDE POLYMORPHISMS USEFUL FOR PREDICTING CLINICAL RESPONSE TO GLATIRAMERATE ACETATE
EP2788017B1 (en) * 2011-12-05 2017-05-31 Ben-Gurion University of The Negev Research and Development Authority INHIBITORS OF IgG-A2BG2 FOR USE IN TREATING AND DIAGNOSING AMYOTROPHIC LATERAL SCLEROSIS
JP6276252B2 (ja) * 2012-03-26 2018-02-07 イェダ リサーチ アンド ディベロップメント カンパニー リミテッドＹｅｄａ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏ． Ｌｔｄ アルツハイマー病の診断のための細胞マーカーおよびアルツハイマー病の進行の細胞マーカー
EP2892353A4 (en) 2012-09-10 2016-10-26 Yeda Res & Dev INDIVIDUALIZED IMMUNOMODULATION THERAPY FOR NEURODEGENERATIVE ILLNESSES, CNS LESIONS AND AGGREGATIVE DEMENTIA
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
US11167003B2 (en) 2017-03-26 2021-11-09 Mapi Pharma Ltd. Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using sustained release glatiramer depot systems

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36670A (en) * 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
US3849650A (en) 1973-03-29 1974-11-19 Picker Corp Automatic x-ray inspection system
US5800808A (en) * 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
SE505316C2 (sv) * 1995-10-17 1997-08-04 Kenneth G Haglid Användning av proteinet S-100b för framställning av läkemedel för nervceller
US20030108528A1 (en) * 1998-05-19 2003-06-12 Michal Eisenbach-Schwartz Activated t-cells, nervous system-specific antigens and their uses
US20020072493A1 (en) * 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
WO1999060021A2 (en) 1998-05-19 1999-11-25 Yeda Research And Development Co. Ltd. Use of activated t cells, nervous system-specific antigens for treating disorders of the nevrous system
EP1039929A1 (en) 1998-07-21 2000-10-04 YEDA RESEARCH AND DEVELOPMENT Co. Ltd. Activated t-cells and their uses
JP2003521448A (ja) 1998-07-23 2003-07-15 ザ・プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ 合成ペプチドおよび自己免疫疾患治療のための使用方法
JP4328050B2 (ja) * 2000-01-20 2009-09-09 イエダ リサーチ アンド デベロップメント カンパニー リミテッド 神経保護療法のためのコポリマー１、関連ペプチド及びポリペプチドならびにそれらによって処理されたｔ細胞の使用
WO2001093893A2 (en) * 2000-06-07 2001-12-13 Yeda Research And Development Co. Ltd. The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy
WO2002076503A1 (en) * 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
US7399740B2 (en) * 2001-06-28 2008-07-15 Yeda Research And Development Co. Ltd. Poly-Glu,Tyr for neuroprotective therapy
US6835711B2 (en) * 2001-06-28 2004-12-28 Yeda Research And Development Co. Ltd. Use of poly-Glu,Tyr for neuroprotective therapy

Also Published As

Publication number Publication date
CN102151330A (zh) 2011-08-17
KR20040081431A (ko) 2004-09-21
HU228207B1 (hu) 2013-01-28
MXPA04005537A (es) 2004-11-01
JP4542339B2 (ja) 2010-09-15
DK1429800T3 (da) 2009-04-27
RU2303996C2 (ru) 2007-08-10
EP1429800A2 (en) 2004-06-23
IL160105A0 (en) 2004-06-20
IS7296A (is) 2004-06-03
AU2002353486A1 (en) 2003-06-17
SI1429800T1 (sl) 2009-08-31
AU2002353486B2 (en) 2009-01-15
US20050220802A1 (en) 2005-10-06
HK1067043A1 (en) 2005-04-01
NO336231B1 (no) 2015-06-22
EP1429800B1 (en) 2009-02-11
EP1429800A4 (en) 2006-03-22
ATE422362T1 (de) 2009-02-15
NZ533356A (en) 2006-10-27
DE60231131D1 (de) 2009-03-26
CA2469092C (en) 2013-02-19
CY1109044T1 (el) 2014-07-02
PT1429800E (pt) 2009-04-27
WO2003047500A3 (en) 2004-03-18
PL370070A1 (en) 2005-05-16
WO2003047500A2 (en) 2003-06-12
CN1617736A (zh) 2005-05-18
RU2004120536A (ru) 2005-03-27
ES2322566T3 (es) 2009-06-23
PL205469B1 (pl) 2010-04-30
CN102151330B (zh) 2017-04-12
CA2469092A1 (en) 2003-06-12
US7351686B2 (en) 2008-04-01
HUP0500039A3 (en) 2010-01-28
HUP0500039A2 (hu) 2005-03-29
JP2005515198A (ja) 2005-05-26
NO20042833L (no) 2004-08-12

Similar Documents

Publication Publication Date Title
IS2670B (is) Bóluefni og notkun þar á til meðhöndlunar á blandaðri hreyfitaugahrörnun
MXPA05002814A (es) Formulacion para agentes lipofilicos.
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
WO2002009746A8 (en) Vaccines comprising outer membrane vesciles from gram negative bacteria
IL125590A (en) Peptide immunogens, process for their preparation and use thereof as vaccines against allergies
DE60239707D1 (de) Antimikrobielle kationische peptide und diese enthaltende formulierungen
CY1110727T1 (el) Παρασκευασματα θετικων κατα gram βακτηριων για τη θεραπεια ασθενειων που περιλαμβανουν μια ανοσολογικη δυσρυθμιση
DE60233898D1 (de) Transdermales therapeutisches system für parkinson-krankheit mit hohen rotigotin-plasmaspiegeln
HK1068606A1 (en) Novel aminobenzoephenones
AU7242796A (en) Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
EP1471936A4 (en) HIV VACCINE AND METHOD OF USE
MXPA02005563A (es) Formulacion estable de interferon en solucion acuosa, metodo de preparacion y usos de la misma.
EP1958960A3 (en) A process for the preparation of a non-toxic anthrax vaccine
BRPI0406858A (pt) Liberação controlada de agentes altamente solúveis
MXPA02010173A (es) Antigenos de leishmania para utilizarse en la terapia y el diagnostico de leishmaniasis.
ATE515258T1 (de) Mukosales verabreichungssytem
MXPA02011533A (es) Nuevas formulaciones de alfa-2,4-disulfofenil-n-terc-butilnitrona.
WO1998035045A3 (en) Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
DK1268522T3 (da) LH-RH-antagonister samt fremstilling deraf og anvendelse deraf som lægemidler
WO2002098359A3 (en) Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
IT1277926B1 (it) Uso di muteine di citochine naturali come immunogeni per la preparazione di composizioni farmaceutiche per curare o prevenire
HUP0402160A2 (hu) T-sejt-epitópok a karboxipeptidáz-G2-ben
RU2350351C2 (ru) Композиции и лекарственные формы на основе гастрина, методы применения и получения
EP1422238A3 (en) Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
AU4300700A (en) Inactivated cytokines for immunisation